Literature DB >> 16027572

Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.

Madhu D Hardasmalani1, Vincent DeBari, William G Bithoney, Nina Gold.   

Abstract

OBJECTIVE: To compare levalbuterol and racemic albuterol for the treatment of acute exacerbation of asthma in pediatric population.
DESIGN: Prospective, double-blind, randomized research trial in a pediatric emergency department of an urban tertiary care hospital. PARTICIPANTS: Children 5 to 21 years with a history of asthma presenting to the emergency department in acute exacerbation.
INTERVENTIONS: As per a computer-generated randomization sequence, patients received either 1.25 mg of levalbuterol or albuterol 2.5 mg via nebulization along with ipratropium hydrochloride. Patients received 3 back-to-back treatments as needed every 20 minutes, maximum of 3; 2 mg/kg of oral prednisone was administered to the patients after the second treatment. Baseline respiratory parameters such as oxygen saturations, respiratory rates, and peak flow rates were measured and repeated after every treatment.The decision for further treatments and or hospitalization was made by the treating emergency department physician as per his/her clinical judgement of the respiratory parameters at the end of 3 treatments.
RESULTS: Seventy patients completed the study. Most of the patients were in moderate severity of asthma exacerbation. All patients in both groups showed improvement in oxygen saturations, respiratory rates, and peak flow rates. However, no statistically significant difference was observed in the 2 groups regarding the respiratory parameters (P > 0.05).
CONCLUSION: Levalbuterol is not more efficacious than racemic albuterol in improving respiratory parameters in children presenting with acute exacerbation of asthma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027572     DOI: 10.1097/01.pec.0000169433.91196.6a

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  9 in total

1.  Management of severe asthma exacerbation in children.

Authors:  Xiao-Fang Wang; Jian-Guo Hong
Journal:  World J Pediatr       Date:  2011-10-20       Impact factor: 2.764

2.  Effects of (r,r)- and (r,r/s,s)-formoterol on airway relaxation and contraction in an experimental rat model.

Authors:  Maroun J Mhanna; Jeffrey F Koester; Robert C Cohn
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

3.  Chiral Switch Drugs for Asthma and Allergies: True Benefit or Marketing Hype.

Authors:  Kathryn Blake; Hengameh Raissy
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-09       Impact factor: 1.349

4.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

5.  Comparison of levalbuterol and racemic albuterol based on cardiac adverse effects in children.

Authors:  Laura L Bio; Vincent J Willey; Cathy Y Poon
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

6.  Pediatric respiratory distress: California out-of-hospital protocols and evidence-based recommendations.

Authors:  Tabitha Cheng; Jennifer Farah; Nicholas Aldridge; Sharon Tamir; J Joelle Donofrio-Odmann
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-06-08

7.  Addition of levalbuterol to a pediatric emergency department automated medication management system does not increase its use.

Authors:  Gregory P Conners; Daniel P Hays; Thomas Richardson; Frank L Zwemer
Journal:  Int J Emerg Med       Date:  2009-12-11

8.  Levalbuterol versus albuterol.

Authors:  Bill T Ameredes; William J Calhoun
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

Review 9.  Levalbuterol for asthma: a better treatment?

Authors:  H William Kelly
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.